Financial Avengers Inc. Sells 42 Shares of Eli Lilly and Company (NYSE:LLY)

Financial Avengers Inc. lowered its position in Eli Lilly and Company (NYSE:LLY) by 2.8% during the fourth quarter, Holdings Channel reports. The firm owned 1,455 shares of the company’s stock after selling 42 shares during the period. Eli Lilly and Company comprises 0.5% of Financial Avengers Inc.’s portfolio, making the stock its 24th largest holding. Financial Avengers Inc.’s holdings in Eli Lilly and Company were worth $1,123,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LLY. Grassi Investment Management raised its position in shares of Eli Lilly and Company by 0.3% during the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company’s stock worth $61,383,000 after purchasing an additional 225 shares during the period. Elevate Capital Advisors LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth about $262,000. Capital & Planning LLC grew its holdings in shares of Eli Lilly and Company by 15.6% in the fourth quarter. Capital & Planning LLC now owns 481 shares of the company’s stock valued at $371,000 after acquiring an additional 65 shares in the last quarter. J2 Capital Management Inc purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $357,000. Finally, Oak Ridge Investments LLC raised its position in Eli Lilly and Company by 6.2% in the fourth quarter. Oak Ridge Investments LLC now owns 55,243 shares of the company’s stock worth $42,648,000 after acquiring an additional 3,201 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on LLY shares. Citigroup decreased their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Hsbc Global Res cut Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Finally, Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 1.2%

Shares of LLY stock opened at $745.72 on Wednesday. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock has a market cap of $706.75 billion, a P/E ratio of 63.68, a P/E/G ratio of 1.40 and a beta of 0.48. The stock has a 50 day moving average of $795.44 and a 200 day moving average of $804.82. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. During the same period last year, the company posted $2.58 earnings per share. The business’s quarterly revenue was up 45.2% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company’s payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.